Merck Beats Street in Q4, but Cautious 2026 Forecast Reflects Patent Cliff

Pharmaceutical giant Merck & Co. reported stronger-than-expected quarterly profits on Thursday, but its tempered forecast for the full year underscores a significant challenge ahead: the loss of patent protection for key drugs. The company's 2026 financial guidance, while projecting growth, landed below analyst expectations, sending a clear signal to investors about the impact of impending generic competition.

Merck's performance in the final quarter of 2025 was robust, driven by continued strong sales of its cancer immunotherapy Keytruda and HPV vaccine Gardasil. This strength, however, is set against a backdrop of change. Later this year, exclusivity for several important medicines is scheduled to expire, opening the door for lower-cost generic alternatives to enter the market.

The company's leadership acknowledged this transition. "Our results demonstrate the current momentum in our business," a Merck spokesperson stated, "while our guidance for 2026 reflects a measured view of the evolving market dynamics we will navigate." The strategy moving forward hinges on the company's pipeline of experimental drugs and recent acquisitions aimed at launching new products to eventually offset the revenue decline from older blockbusters. The coming year is widely seen within the industry as a pivotal period for Merck as it manages this transition under the economic policies of the Trump administration, now in its second year.

Source: CNBC